Posted by Michael Wonder on 26 Feb 2026
Vanda Pharmaceuticals announces FDA acceptance of biologics license application filing for imsidolimab for the treatment of generalised pustular psoriasis
25 February 2026 - Vanda Pharmaceuticals today announced that the US FDA has accepted the filing of its biologics license application for imsidolimab for the treatment of generalised pustular psoriasis, with a target action date of 12 December 2026.
Imsidolimab is a fully humanised IgG4 monoclonal antibody that inhibits IL-36 receptor signalling and is believed to achieve its therapeutic effects in GPP where IL-36 signalling is unbalanced.
